278 related articles for article (PubMed ID: 38114959)
1. Systematic analysis based on the cuproptosis-related genes identifies ferredoxin 1 as an immune regulator and therapeutic target for glioblastoma.
Dai L; Zhou P; Lyu L; Jiang S
BMC Cancer; 2023 Dec; 23(1):1249. PubMed ID: 38114959
[TBL] [Abstract][Full Text] [Related]
2. Identification of cuproptosis-related subtypes, construction of a prognosis model, and tumor microenvironment landscape in gastric cancer.
Wang J; Qin D; Tao Z; Wang B; Xie Y; Wang Y; Li B; Cao J; Qiao X; Zhong S; Hu X
Front Immunol; 2022; 13():1056932. PubMed ID: 36479114
[TBL] [Abstract][Full Text] [Related]
3. Construction and validation of a cuproptosis-related prognostic model for glioblastoma.
Zhang B; Xie L; Liu J; Liu A; He M
Front Immunol; 2023; 14():1082974. PubMed ID: 36814929
[TBL] [Abstract][Full Text] [Related]
4. Multi-omics pan-cancer study of cuproptosis core gene
Xu J; Hu Z; Cao H; Zhang H; Luo P; Zhang J; Wang X; Cheng Q; Li J
Front Immunol; 2022; 13():981764. PubMed ID: 36605188
[TBL] [Abstract][Full Text] [Related]
5. EREG is the core onco-immunological biomarker of cuproptosis and mediates the cross-talk between VEGF and CD99 signaling in glioblastoma.
Zhou Y; Xiao D; Jiang X; Nie C
J Transl Med; 2023 Jan; 21(1):28. PubMed ID: 36647156
[TBL] [Abstract][Full Text] [Related]
6. Identification of cuproptosis-related subtypes and the development of a prognostic model in glioma.
Wu Z; Li W; Zhu H; Li X; Zhou Y; Chen Q; Huang H; Zhang W; Jiang X; Ren C
Front Genet; 2023; 14():1124439. PubMed ID: 36936439
[No Abstract] [Full Text] [Related]
7. Development of a prognostic model for glioblastoma multiforme based on the expression levels of efferocytosis-related genes.
Xu W; Han L; Zhu P; Cheng Y; Chen X
Aging (Albany NY); 2023 Dec; 15(24):15578-15598. PubMed ID: 38159261
[TBL] [Abstract][Full Text] [Related]
8. Comprehensive analysis of cuproptosis-related immune biomarker signature to enhance prognostic accuracy in gastric cancer.
Li J; Yu T; Sun J; Zeng Z; Liu Z; Ma M; Zheng Z; He Y; Kang W
Aging (Albany NY); 2023 Apr; 15(7):2772-2796. PubMed ID: 37036489
[TBL] [Abstract][Full Text] [Related]
9. Cuproptosis-related gene
Wang T; Liu Y; Li Q; Luo Y; Liu D; Li B
Front Immunol; 2022; 13():999823. PubMed ID: 36225932
[TBL] [Abstract][Full Text] [Related]
10. Relationships of Cuproptosis-Related Genes With Clinical Outcomes and the Tumour Immune Microenvironment in Hepatocellular Carcinoma.
Chen X; Hu G; Xiong L; Xu Q
Pathol Oncol Res; 2022; 28():1610558. PubMed ID: 36213162
[No Abstract] [Full Text] [Related]
11. Targeting copper death genotyping associated gene RARRES2 suppresses glioblastoma progression and macrophages infiltration.
Yan T; Yang H; Meng Y; Li H; Jiang Q; Liu J; Xu C; Xue Y; Xu J; Song Y; Chu X; Wang L; Chen X; Che F
Cancer Cell Int; 2023 May; 23(1):105. PubMed ID: 37246211
[TBL] [Abstract][Full Text] [Related]
12. Association Between Diverse Cell Death Patterns Related Gene Signature and Prognosis, Drug Sensitivity, and Immune Microenvironment in Glioblastoma.
Li J; Song Z; Chen Z; Gu J; Cai Y; Zhang L; Wang Z
J Mol Neurosci; 2024 Jan; 74(1):10. PubMed ID: 38214842
[TBL] [Abstract][Full Text] [Related]
13. Development and validation a prognostic model based on natural killer T cells marker genes for predicting prognosis and characterizing immune status in glioblastoma through integrated analysis of single-cell and bulk RNA sequencing.
Hu J; Xu L; Fu W; Sun Y; Wang N; Zhang J; Yang C; Zhang X; Zhou Y; Wang R; Zhang H; Mou R; Du X; Li X; Hu S; Xie R
Funct Integr Genomics; 2023 Aug; 23(3):286. PubMed ID: 37650991
[TBL] [Abstract][Full Text] [Related]
14. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
[TBL] [Abstract][Full Text] [Related]
15. Pan-cancer integrated bioinformatics analysis reveals cuproptosis related gene FDX1 is a potential prognostic and immunotherapeutic biomarker for lower-grade gliomas.
Huang W; Wu Y; Zhu J; Luo N; Wang C; Liu S; Cheng Z
Front Mol Biosci; 2023; 10():963639. PubMed ID: 36825202
[TBL] [Abstract][Full Text] [Related]
16. A cuproptosis random forest cox score model-based evaluation of prognosis, mutation characterization, immune infiltration, and drug sensitivity in hepatocellular carcinoma.
Liu R; Liu Y; Zhang F; Wei J; Wu L
Front Immunol; 2023; 14():1146411. PubMed ID: 37063920
[TBL] [Abstract][Full Text] [Related]
17. Construction and validation of a novel cuproptosis-mitochondrion prognostic model related with tumor immunity in osteosarcoma.
Feng J; Wang J; Xu Y; Lu F; Zhang J; Han X; Zhang C; Wang G
PLoS One; 2023; 18(7):e0288180. PubMed ID: 37405988
[TBL] [Abstract][Full Text] [Related]
18. Characterization of cuproptosis identified immune microenvironment and prognosis in acute myeloid leukemia.
Luo D; Liu S; Luo J; Chen H; He Z; Gao Z; Wen Z; Liu X; Xu N
Clin Transl Oncol; 2023 Aug; 25(8):2393-2407. PubMed ID: 36826709
[TBL] [Abstract][Full Text] [Related]
19. A novel cuproptosis-related gene signature to predict prognosis in Glioma.
Zhang M; Liu X; Wang D; Ruan X; Wang P; Liu L; Xue Y
BMC Cancer; 2023 Mar; 23(1):237. PubMed ID: 36915038
[TBL] [Abstract][Full Text] [Related]
20. Development and validation of cuproptosis-related lncRNAs associated with pancreatic cancer immune microenvironment based on single-cell.
Sun Y; Yao L; Man C; Gao Z; He R; Fan Y
Front Immunol; 2023; 14():1220760. PubMed ID: 37822927
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]